The TNF Receptor-Associated Autoinflammatory Syndrome (TRAPS)

  • Marco Gattorno


The TNF receptor-associated autoinflammatory syndrome (TRAPS, MIM 142680), formerly known as familial Hibernian fever [1], is a rare dominantly inherited disorder, caused by mutations in the p55 TNF receptor (or TNFR1), encoded by the TNF superfamily receptor 1A (TNFRSF1A) gene [2]. The disease was originally identified in families of Northern European ancestry but has been described in almost all ethnic groups, including those living in Mediterranean countries and Asia. Fever is often prolonged and can be accompanied by serositis, arthritis, a skin rash with underlying fasciitis and periorbital oedema.


  1. 1.
    Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BH, Toghill PJ. Familial Hibernian fever. Q J Med. 1982;51(204):469–80.PubMedGoogle Scholar
  2. 2.
    McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133–44.CrossRefGoogle Scholar
  3. 3.
    Touitou I, Lesage S, McDermott M, Cuisset L, Hoffman H, Dode C, et al. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat. 2004;24(3):194–8.CrossRefGoogle Scholar
  4. 4.
    Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet. 2001;69(2):301–14.CrossRefGoogle Scholar
  5. 5.
    Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum. 2003;48(9):2632–44.CrossRefGoogle Scholar
  6. 6.
    Siebert S, Amos N, Fielding CA, Wang EC, Aksentijevich I, Williams BD, et al. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis Rheum. 2005;52(4):1287–92.CrossRefGoogle Scholar
  7. 7.
    D'Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis – Pathogenetic and clinical implications. Arthritis Rheum. 2006;54(3):998–1008.CrossRefGoogle Scholar
  8. 8.
    Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood. 2006;108(4):1320–7.CrossRefGoogle Scholar
  9. 9.
    Simon A, Park H, Maddipati R, Lobito AA, Bulua AC, Jackson AJ, et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A. 2010;107(21):9801–6.CrossRefGoogle Scholar
  10. 10.
    Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med. 2011;208(3):519–33.CrossRefGoogle Scholar
  11. 11.
    Hasnain SZ, Lourie R, Das I, Chen AC, McGuckin MA. The interplay between endoplasmic reticulum stress and inflammation. Immunol Cell Biol. 2012;90(3):260–70.CrossRefGoogle Scholar
  12. 12.
    Torene R, Nirmala N, Obici L, Cattalini M, Tormey V, Caorsi R, et al. Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis. 2017;76(1):303–9.CrossRefGoogle Scholar
  13. 13.
    Bachetti T, Chiesa S, Castagnola P, Bani D, Di ZE, Omenetti A, et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis. 2013;72(6):1044–52. Epub 2012 Oct 31.CrossRefGoogle Scholar
  14. 14.
    Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature. 2008;456(7219):264–8.CrossRefGoogle Scholar
  15. 15.
    Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12(3):222–30.CrossRefGoogle Scholar
  16. 16.
    Tassi S, Carta S, Delfino L, Caorsi R, Martini A, Gattorno M, et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion. Proc Natl Acad Sci U S A. 2010;107(21):9789–94.CrossRefGoogle Scholar
  17. 17.
    Rubartelli A, Gattorno M, Netea MG, Dinarello CA. Interplay between redox status and inflammasome activation. Trends Immunol. 2011;32(12):559–66.CrossRefGoogle Scholar
  18. 18.
    Toplak N, Dolezalova P, Constantin T, Sediva A, Pasic S, Ciznar P, et al. Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey. Pediatr Rheumatol Online J. 2010;8:29.CrossRefGoogle Scholar
  19. 19.
    Lachmann HJ, Meini A, Touitou I, Obici L, Finetti M, Minden K, et al. Demographic and Genetic Results From the EUROFEVERS/EUROTRAPS Consortia in the Largest Series of Patients with TRAPS Yet Reported. Arthritis Rheum. 2011;63(10):S386–7.Google Scholar
  20. 20.
    Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore). 2002;81(5):349–68.CrossRefGoogle Scholar
  21. 21.
    Yao Q, Englund KA, Hayden SP, Tomecki KJ. Tumor necrosis factor receptor associated periodic fever syndrome with photographic evidence of various skin disease and unusual phenotypes: case report and literature review. Semin Arthritis Rheum. 2012;41(4):611–7.CrossRefGoogle Scholar
  22. 22.
    Hull KM, Wong K, Wood GM, Chu WS, Kastner DL. Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum. 2002;46(8):2189–94.CrossRefGoogle Scholar
  23. 23.
    Federici S, Sormani MP, Ozen S, Lachmann HJ, Amaryan G, Woo P, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015;74(5):799–805.CrossRefGoogle Scholar
  24. 24.
    Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013;72(5):678–85. Epub 2012 Jun 29. Review.CrossRefGoogle Scholar
  25. 25.
    Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology. 2003;42(2):235–9.CrossRefGoogle Scholar
  26. 26.
    Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford). 2004;43(11):1405–8.CrossRefGoogle Scholar
  27. 27.
    Kallinich T, Briese S, Roesler J, Rudolph B, Sarioglu N, Blankenstein O, et al. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol. 2004;31(12):2519–22.PubMedGoogle Scholar
  28. 28.
    Jesus AA, Oliveira JB, Aksentijevich I, Fujihira E, Carneiro-Sampaio MM, Duarte AJ, et al. TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept. Eur J Pediatr. 2008;167(12):1421–5.CrossRefGoogle Scholar
  29. 29.
    Weyhreter H, Schwartz M, Kristensen TD, Valerius NH, Paerregaard A. A new mutation causing autosomal dominant periodic fever syndrome in a Danish family. J Pediatr. 2003;142(2):191–3.CrossRefGoogle Scholar
  30. 30.
    Simon A, Bodar EJ, van der Hilst JC, van der Meer JW, Fiselier TJ, Cuppen MP, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med. 2004;117(3):208–10.CrossRefGoogle Scholar
  31. 31.
    Arostegui JI, Solis P, Aldea A, Cantero T, Rius J, Bahillo P, et al. Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr. 2005;164(1):13–6.CrossRefGoogle Scholar
  32. 32.
    Jacobelli S, Andre M, Alexandra JF, Dode C, Papo T. Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). Rheumatology (Oxford). 2007;46:1211.CrossRefGoogle Scholar
  33. 33.
    Drewe E, Powell RJ, McDermott EM. Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford). 2007;46(12):1865–6.CrossRefGoogle Scholar
  34. 34.
    Bulua AC, Mogul DB, Aksentijevich I, Singh H, He D, Muenz L, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Arthritis Rheum. 2012;64(3):908–13. Scholar
  35. 35.
    Siebert S, Amos N, Lawson TM. Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford). 2008;47(2):228–9.CrossRefGoogle Scholar
  36. 36.
    Sacre K, Brihaye B, Lidove O, Papo T, Pocidalo MA, Cuisset L, et al. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol. 2008;35(2):357–8.PubMedGoogle Scholar
  37. 37.
    Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008;58(5):1516–20.CrossRefGoogle Scholar
  38. 38.
    Brizi MG, Galeazzi M, Lucherini OM, Cantarini L, Cimaz R. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med. 2012;156(12):907–8.CrossRefGoogle Scholar
  39. 39.
    Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2017;76(1):173–8.CrossRefGoogle Scholar
  40. 40.
    De Benedetti F, Anton J, Gattorno M, Lachmann H, Kone-Paut I, Ozen S, et al. A phase III pivotal umbrella trial of canakinumab in patients with autoinflammatory periodic fever syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). Ann Rheum Dis. 75(Suppl 2):615–6.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.UO Pediatria IIGenoaItaly

Personalised recommendations